# AcouSort > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/acousort). ## Overview AcouSort is a Swedish medical technology company that develops acoustofluidic sample-preparation systems and OEM components for life science instrumentation. Its products are used to automate the handling, separation, washing, trapping, and preparation of biological samples in diagnostics, cell therapy, and laboratory workflows. ## Products & services • OEM sample-preparation components for instrument makers • AcouWash benchtop system for automated cell separation • AcouTrap benchtop system for trapping and enrichment • AcouPlasmaOptical OEM component for plasma processing • Evaluation kits and integration support for partners • Custom sample-flow and electronic interfacing solutions - **OEM components** (45%) — Acoustofluidic modules and components embedded into third-party diagnostic and therapeutic instruments. - **Research and innovation systems** (30%) — Benchtop AcouWash and AcouTrap systems used for evaluation, development, and workflow validation. - **License fees** (15%) — Technology licensing and related rights tied to use of AcouSort's platform. - **Product sales and services** (10%) — Sales of systems, kits, and technical services supporting customer integration projects. - OEM sample-preparation components for instrument makers - AcouWash benchtop system for automated cell separation - AcouTrap benchtop system for trapping and enrichment - AcouPlasmaOptical OEM component for plasma processing - Evaluation kits and integration support for partners - Custom sample-flow and electronic interfacing solutions ## Customers AcouSort sells primarily to life science instrument manufacturers that want to embed automated sample-preparation steps into diagnostic, analytics, and cell-therapy systems. It also works with universities, research institutions, and industrial partners that use AcouWash and AcouTrap for feasibility studies, workflow development, and scientific validation. - **Life science OEMs** (primary) — Buy OEM components and integration support to embed automated sample processing into instruments. - **Cell therapy developers** (primary) — Use the technology to automate cell washing, separation, and handling in manufacturing workflows. - **Diagnostics companies** (primary) — Evaluate AcouSort's platform for blood, plasma, and cell-processing steps in diagnostic systems. - **Research institutions** (secondary) — Buy benchtop systems and evaluation kits for scientific studies and workflow validation. - **Industrial manufacturers** (emerging) — Explore particle-removal and process-integration use cases in production workflows. - OEM instrument manufacturers integrating sample-prep into devices - Cell therapy and bioprocessing companies automating workflows - Diagnostic system developers evaluating separation and washing steps - Universities and research institutes using benchtop platforms - Industrial manufacturers testing particle-removal applications ## Geography AcouSort is headquartered in Sweden and serves customers across North America, Europe, and selected markets in Asia. The company also operates a U.S. subsidiary, AcouSort Inc., to support marketing and sales in North America, while its systems and partnerships are used internationally across research and commercial settings. - Sweden is the corporate base and operating center - North America is supported through AcouSort Inc. in the U.S. - Europe is a core market for OEM and research collaborations - Asia is part of the company's expanding commercial footprint - International sales depend on partner adoption and local validation ## Strategy AcouSort's strategy is to convert its acoustofluidics platform from technology validation into broader OEM adoption and recurring commercial use. The company focuses on partnerships with instrument makers, cell-therapy developers, and research institutions to prove integration, build scientific credibility, and create pathways to long-term agreements. - **OEM-driven commercialization** (short-term) — Embedded components can create repeatable revenue and deeper customer integration. - **Convert feasibility work into long-term agreements** (medium-term) — Pilot projects are the main route to scaled adoption in regulated life science workflows. - **Broaden application areas** (medium-term) — Multiple end markets reduce dependence on any single workflow or customer type. - **Strengthen scientific validation** (long-term) — Publications and conference exposure help de-risk adoption for OEM and research buyers. - Win OEM design-ins with life science instrument manufacturers - Convert feasibility projects into long-term commercial agreements - Use AcouWash and AcouTrap as validation platforms - Expand in cell therapy, diagnostics, and lab automation - Leverage scientific publications and conference visibility - Build international reach through direct and partner-led sales ## Risks AcouSort is exposed to commercialization risk because its business depends on converting technical validation into customer adoption and OEM agreements. It also faces liquidity, technology, regulatory, and competition risks typical of early-stage medtech and life science tools companies, where development cycles are long and outcomes are uncertain. - **Liquidity risk** [high] — The company relies on ongoing sales, grants, and funding to support operations before scale is reached. - **Commercialization risk** [high] — Revenue depends on turning pilots and evaluations into OEM contracts and repeat orders. - **Technology development risk** [medium] — The platform must continue to perform reliably across different biological workflows and customer systems. - **Competition risk** [medium] — Customers can choose alternative sample-preparation technologies or in-house solutions. - **Regulatory and quality risk** [medium] — Medical and life science customers require validated processes and quality systems. - Commercial adoption may lag if feasibility projects do not convert - Liquidity depends on sales, grants, and continued funding access - Technology risk remains if performance is not proven at scale - Competition from alternative sample-prep methods can slow adoption - Regulatory and quality requirements can delay customer rollouts - Foreign exchange and international expansion add execution risk ## Accounting Revenue recognition is judgmental because the company earns a mix of product sales, license fees, services, and project-related income that may be recognized at different points in time. Investors should also watch public grants, capitalized development costs, leases, and any estimates tied to going-concern liquidity and project accruals, since these can materially affect reported results. - **Revenue recognition** — Can shift revenue between quarters and affect comparability. - **Public grants** — Can materially affect other income and R&D funding visibility. - **Capitalized development and patents** — Affects asset values, amortization, and reported earnings. - **Operating leases** — Affects operating costs and fixed commitments. - **Liquidity and accrual estimates** — Can influence going-concern assessment and expense accruals. - Mixed revenue streams require different recognition timing - License fees and project income can create quarter-to-quarter volatility - Public grants affect reported income and R&D funding visibility - Capitalized development and patent costs affect intangible assets - Operating leases for labs and offices affect fixed-cost structure - Liquidity and accrual estimates can influence going-concern judgments --- *Last updated: 2026-08-11T04:04:50.663078+00:00*